Published in Antimicrob Agents Chemother on May 01, 2000
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol (2006) 2.33
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry (2006) 1.11
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. J Virol (2007) 1.06
Evolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypes. PLoS Comput Biol (2008) 1.05
Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother (2005) 0.92
A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. BMC Bioinformatics (2011) 0.89
HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) (2015) 0.82
Review of tipranavir in the treatment of drug-resistant HIV. Ther Clin Risk Manag (2007) 0.79
Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes. Antimicrob Agents Chemother (2011) 0.78
Tipranavir in the protease inhibitors arena. Drugs R D (2011) 0.75
New Drugs for the Treatment of HIV Infection. Curr Infect Dis Rep (2001) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis (1998) 1.89
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis (1996) 1.58
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS (1999) 1.05
Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol (1999) 0.95
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother (1997) 0.95
Virological and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist Updat (1998) 0.89
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2009) 4.95
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost (2007) 2.86
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis (2001) 2.50
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.96
Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65
Disseminated human herpesvirus 6 infection in AIDS. Lancet (1993) 1.64
Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat (2009) 1.62
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
Epidemiology of post-infarction risk stratification strategies in a country with a low volume of revascularization procedures. GISSI-Prognosis Investigators. Eur Heart J (1998) 1.56
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost (1991) 1.55
Accuracy and reliability of frozen section diagnosis in a series of 672 nonpalpable breast lesions. Am J Clin Pathol (1995) 1.51
Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis. J Infect Dis (1989) 1.48
High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1--associated predominantly sensory polyneuropathy. J Infect Dis (1995) 1.47
Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression. Br J Pharmacol (2009) 1.45
Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol (1996) 1.45
Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev (1994) 1.42
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS (2001) 1.41
Thallium-201 reverse redistribution at reinjection imaging correlated with coronary lesion, wall motion abnormality and tissue viability. J Nucl Med (1996) 1.41
Increased levels of beta 2-glycoprotein I (aca-Cofactor) in patients with lupus anticoagulant. Thromb Haemost (1992) 1.39
Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology (2000) 1.39
Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Lancet (1990) 1.38
Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol (1986) 1.37
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res (1998) 1.36
Terrestrial gamma-ray flashes as powerful particle accelerators. Phys Rev Lett (2011) 1.35
Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J Immunol (1991) 1.32
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet (1986) 1.31
Clinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-resistant strains. Antimicrob Agents Chemother (1986) 1.31
Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr (2001) 1.31
Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis (1985) 1.29
Use of the normalcy index for the evaluation of gait pathology. Gait Posture (2004) 1.28
Inguino-scrotal hernia of a double district ureter: case report and literature review. Hernia (2005) 1.28
Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol (1996) 1.27
Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. Clin Exp Immunol (1985) 1.24
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 1.23
AIDS-defining diseases in 250 HIV-infected patients; a comparative study of clinical and autopsy diagnoses. AIDS (1992) 1.20
Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry (1996) 1.19
Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol (2001) 1.18
Biomechanical analysis of sit-to-stand movement in normal and obese subjects. Clin Biomech (Bristol, Avon) (2003) 1.17
Reproductive history and gastric cancer among post-menopausal women. Int J Cancer (1994) 1.16
Pseudomonas infections in patients with AIDS and AIDS-related complex. J Intern Med (1992) 1.16
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther (2000) 1.16
Discovery of powerful gamma-ray flares from the Crab Nebula. Science (2011) 1.13
Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res (1995) 1.13
Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors. Clin Exp Immunol (2002) 1.13
Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica (1997) 1.12
Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther (1998) 1.10
Doxorubicin/methotrexate/fluorouracil in advanced pancreatic cancer. Lancet (1990) 1.09
Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur Heart J (1988) 1.08
[Contribution of immunofluorescence tests to the biological diagnosis of hydatidosis]. G Mal Infett Parassit (1966) 1.08
Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol (1987) 1.08
Focal lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): a correlative morphologic and clinical study in 26 consecutive fatal cases. J Am Coll Cardiol (1988) 1.07
Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res (1983) 1.07
A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). Scand J Gastroenterol (1996) 1.06
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med (2010) 1.05
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood (2001) 1.05
Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses (1996) 1.05
Scrotal angiokeratoma (Fordyce): histopathological and ultrastructural findings. Histol Histopathol (1992) 1.05
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect (2000) 1.04
Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood (1997) 1.04
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol (2001) 1.04
Functional dissection of the cis-acting sequences of the Arabidopsis transposable element Tag1 reveals dissimilar subterminal sequence and minimal spacing requirements for transposition. Genetics (2001) 1.02
AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy. HIV Med (2009) 1.02
Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis (2000) 1.01
Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis (1997) 0.99
Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS (1996) 0.99
Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science (1997) 0.99
Reproducibility of histological diagnosis of breast lesions: results of a panel in Italy. Eur J Cancer (1996) 0.98